文献速递前列腺癌

前列腺癌根治性放疗后PSA反弹的预后价值:系统综述与荟萃分析

Prognostic value of PSA bounce in prostate cancer following definitive radiation therapy: a systematic review and meta-analysis.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2021-05-04

该系统综述与荟萃分析纳入10项研究共8881例接受根治性放疗的局限性前列腺癌患者,其中2706例(30.5%)出现PSA反弹。结果显示PSA反弹与更好的生化无复发生存相关(合并HR:0.62,95%CI:0.54-0.71),亚组分析中低剂量率近距离放疗单独治疗(合并HR:0.38,95%CI:0.27-0.55)和外照射放疗单独治疗(合并HR:0.71,95%CI:0.57-0.87)均显示独立关联。

要点

  • 根治性放疗后PSA反弹与更好的生化无复发生存相关。
  • PSA反弹患者占30.5%(2706/8881),合并HR为0.62。
  • 低剂量率近距离放疗和外照射放疗亚组均显示独立关联。

核心结论

  • 根治性放疗后PSA反弹与前列腺癌患者更好的生化失败结局相关。

研究设计与样本

  • 系统综述与荟萃分析,遵循PRISMA指南,2021年1月检索PubMed、Cochrane图书馆和Scopus,纳入10项研究共8881例局限性前列腺癌患者。

主要发现

  • PSA反弹患者占全部8881例的30.5%(2706例)。
  • PSA反弹与更好的生化无复发生存相关(合并HR:0.62,95%CI:0.54-0.71)。
  • 低剂量率近距离放疗单独治疗亚组中PSA反弹与生化无复发生存风险降低独立相关(合并HR:0.38,95%CI:0.27-0.55)。
  • 外照射放疗单独治疗亚组中PSA反弹与生化无复发生存风险降低独立相关(合并HR:0.71,95%CI:0.57-0.87)。

临床怎么用

  • 对于根治性放疗后出现PSA反弹的前列腺癌患者,可将其视为预后较好的可能信号,避免过度干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The prognostic significance of PSA bounce following definitive radiation therapy remains controversial. To develop a sense of current opinion in this area, we performed a systematic search of the literature based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses. METHODS: In January 2021, we systematically searched PubMed, the Cochrane library, and Scopus for studies that compared patients who had localized prostate cancer with or without PSA bounce after definitive radiation therapy. Our objective was to evaluate the association of PSA bounce with biochemical recurrence-free survival, metastatic-free survival, cancer-specific survival, and overall survival, using multivariate Cox regression analysis. RESULTS: A total of 8881 patients in 10 studies matched the selection criteria for the systematic review and meta-analysis. The number of patients with PSA bounce accounted for 2706 of all 8881 patients (30.5%). PSA bounce was associated with better biochemical recurrence-free survival after definitive radiation therapy (pooled HR: 0.62, 95% CI: 0.54-0.71). Subgroup analyses also showed that PSA bounce was independently associated with decreased risk for biochemical recurrence-free survival in prostate cancer patients treated with low dose rate brachytherapy alone (pooled HR: 0.38, 95% CI: 0.27-0.55) and external beam radiotherapy alone (pooled HR: 0.71, 95% CI: 0.57-0.87). CONCLUSIONS: This meta-analysis indicated that PSA bounce after definitive radiation therapy is related to improved outcome in terms of biochemical failure in prostate cancer patients.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Urabe F, Kimura S, Tashiro K, et al. Prognostic value of PSA bounce in prostate cancer following definitive radiation therapy: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2021. PMID: 33947976. doi:10.1038/s41391-021-00372-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。